Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

https://ift.tt/U2aApDw

FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

from Sanofi - Aventis Groupe https://ift.tt/VwiQgCr
via IFTTT

" May good health envelop you, spurring a quick recovery. .. "

from health care https://ift.tt/nrUY26F
via IFTTT https://ift.tt/CJi79Ba